The good news about Truvada/PrEP continues this week.
Researchers from UCLA, publishing in the Oxford Journal, say that PrEP, as far as they can tell, for short- to medium-term use, is as safe as over-the-counter aspirin for human consumption, and in terms of possible side effects.
As HIV Equal reports:
Researchers from the University of California Los Angeles compared five major studies on PrEP for HIV infection with two major studies on aspirin Safety. Each medication was given a score based on how numbers needed to harm (NNH), or cause a reported side effect.
The report concluded that the use of Truvada as PrEP was favorable to Aspirin in terms of safety, but that more studies on long-term use were needed. Still, those users who have engaged in short or medium term PrEP should be reassured of the drug’s safety.
Per the Oxford Journal piece, “While long-term studies are needed, providers should feel reassured about the safety of short- and medium-term PrEP.”
This news comes a few months after a three-year study of gay men taking PrEP in San Francisco that showed zero new HIV infections, and it comes after a terrific op-ed piece in adult industry publication AVN that explains in detail why the LA-based AIDS Healthcare Foundation has been so bizarrely anti-PrEP — it all comes down to money, of course, and how much less they’ll take in at their HIV testing centers and clinics if everyone gets on PrEP.